Entecavir: A review of its use in chronic hepatitis B

Drugs

Volumn 69, Issue 8, 2009, Pages 1003-1033

  Scott, Lesley J ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Entecavir; Hepatitis B; Nucleoside analogue; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ADEFOVIR DIPIVOXIL; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CHRONIC HEPATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; KIDNEY FAILURE; LIVER FIBROSIS; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; PHARMACODYNAMICS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEROCONVERSION; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ECONOMICS, PHARMACEUTICAL; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

ANIMALIA; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMPLEXVIRUS;

EID: 67149143413     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969080-00005     Document Type: Review

References (84)

1. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008;8 (3): 167-78
2. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5 (8): 921-31
3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3): 678-86
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73
5. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Anti-microb Chemother 2007; 60 (2): 201-5
6. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference statement: management of hepatitis B. Ann Intern Med 2009; 150 (2): 104-10
7. European Association for the Study of the Liver Clinical Practice Guidelines Panel. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-42
8. Keefe EB, Dieterich DT, Han S-H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41
9. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81 (8): 3992-4001
10. Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs 2006; 66 (12): 1605-22; discussion 1623-4
11. Tchesnokov EP, Obikhod A, Schinazi RF, et al. Delayed chain-termination protects the anti-HBV drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem 2008; 283 (49): 34218-28
12. Bristol-Myers Squibb Co. Baraclude® (entecavir) US prescribing information [online]. Available from URL: http://www.baraclude.com/pi.html [Accessed 2009 Jan 5]
13. European Medicines Agency. Baraclude: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ baraclude/H-623-PI-en.pdf [Accessed 2009 Apr 5]
14. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41 (7): 1444-8
15. Mazzucco CE, Hamatake RK, Colonno RJ, et al. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008; 52 (2): 598-605
16. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107 (4): 449-55
17. Lin PF, Nowicka-Sans B, Terry B, et al. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother 2008; 52 (5): 1759-67
18. Domaoal RA, McMahon M, Thio CL, et al. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 2008; 283 (9): 5452-9
19. Audsley J, Sasadeusz J, Mijch A, et al. The anti-HIV activity of entecavir: serum HIV RNA decreases and selection of the M184V mutation occurs in both ART-naive and -experienced HIV/HBV-co-infected individuals [abstract no. 63]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
20. Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV [letter]. AIDS 2007; 21 (17): 2365-6
21. Jakobsen MR, Arildsen H, Krarup HB, et al. Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. Clin Infect Dis 2008; 46 (9): 88-91
22. Castel H, Bocket L, Tamalet C, et al. Entecavir monotherapy selects M184V mutation in lamivudine-naive and lamivudine experienced HIV-HBV co-infected patients [abstract no. 938]. Hepatology 2008; 48 (4 Suppl.): 728
23. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir: effects on HIV-1 replication and resistance. N Engl J Med 2007; 356 (25): 2614-21
24. Wolters LMM, Hansen BE, Niesters HGM, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37 (1): 137-44
25. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. Epub 2009 Feb 4
26. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51 (3): 902-11
27. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside-naive patients with hepatitis B. Hepatology 2006; 44 (6): 1656-65
28. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47 (5): 1473-82
29. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46 (3): 531-8
30. Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus qua-sispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008; 48 (6): 895-902
31. Guo JJ, Li QL, Shi XF, et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009; 81 (2): 180-3
32. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354 (10): 1001-10
33. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivu-dine for patients with HBeAg-negative chronic hepatitis B [published erratum appears in N Engl J Med 2006; 354 (17): 1863]. N Engl J Med 2006; 354 (10): 1011-20
34. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130 (7): 2039-49
35. Suzuki F, Suzuki Y, Akuta N, et al. Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. Hepatol Res 2008; 38 (2): 132-40
36. Kobashi H, Fujioka S-i, Kumada H, et al. Emergence of hepatitis B virus gene mutation related to entecavir-resistance in chronic hepatitis B patients participated in the phase 2 clinical studies of entecavir in Japan [abstract no. 963]. Hepatology 2007 Oct 1; 46 (4 Suppl. 1): 666
37. Mukaide M, Tanaka Y, Orito E, et al. Three-year assessment of entecavir resistance in genotype C chronic hepatitis B patients in Japan reveals different clinical outcomes regarding breakthrough hepatitis predicted by the resistance substitutions using recently developed INNO-LiPA HBV assay [abstract no. 1003]. Hepatology 2007; 46 (4 Suppl. 1): 685
38. Jiang Y, Wang F, Liu Y, et al. The host immunity response of hepatitis B patients after adefovir dipivoxil and entecavir therapy [abstract no. 1610]. Hepatology 2008; 48 (4 Suppl.): 1020-1
39. Lu GF, Tang FA, Zheng PY, et al. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol 2008; 14 (10): 1617-21
40. You J, Sriplung H, Geater A, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123
41. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacoki-netics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006; 46 (11): 1250-8
42. Bifano M, Yan JH, Smith RA, et al. Absence of a pharmacokinetic interaction between entecavir and adefovir. J Clin Pharmacol 2007; 47 (10): 1327-34
43. Zhu M, Bifano M, Xu X, et al. Lack of an effect of human immunodeficiency virus coinfection on the pharmaco-kinetics of entecavir in hepatitis B virus-infected patients. Antimicrob Agents Chemother 2008; 52 (8): 2836-41
44. Lampertico P, Vigano M, Facchetti F, et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice [abstract no. 896]. Hepatology 2008; 48 (4 Suppl.): 707-8
45. Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008; 23 (9): 1320-6
46. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastro-enterology 2005 Oct; 129 (4): 1198-209
47. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1: 365-72
48. Yao G, Zhou X, Xu D, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int 2007; 1 (3): 373-81
49. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133 (5): 1437-44
50. Han S, Chang TT, Chao YC, et al. Four-year entecavir treatment in nucleoside-naive HBEAG(+) patients: results from studies ETV-022 and -901 [abstract no. 938]. Hepato-logy 2007; 46 (4 Suppl. 1): 654
51. Han S-H, Chang T-T, Chao Y-C, et al. Five years of continuous entecavir for nucleoside-naive HBEAG(+) chronic hepatitis B: results from study ETV-901 [abstract no 893]. Hepatology 2008; 48 (4 Suppl.): 705-6
52. Leung N, Peng C-Y, Hann H-W, et al. Early hepatitis B virus DNA reduction in HBeAg-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49 (1): 72-9
53. Leung N, Peng CY, Sollano J, et al. Entecavir results in higher HBV DNA reduction versus adefovir in antiviral-naive HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y. study) [abstract no. 998]. J Hepatol 2008; 48 Suppl. 2: 373-4
54. Senturk H, Lurie Y, Gadano A, et al. ETV re-treatment of nucleoside-naive HBeAg(-) patients [abstract no. 517]. J Hepatol 2007; 46 Suppl. 1: 197
55. Shouval D, Lai C-L, Chang T-T, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50 (2): 289-95
56. Shouval D, Akarca US, Hatzis G, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027) [abstract no. 45]. J Hepatol 2006; 44 Suppl. 2: 21-2
57. Shouval D, Lai C, Chang T, et al. Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901 [abstract no. 927]. Hepatology 2008; 48 (4 Suppl.): 722
58. Yao G, Chen CW, Lu WL, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir or lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicentre study. Hepatol Int 2008: DOI 10.1007/s12072-1008-9088-8
59. Yao GB, Xu DZ, Ren H, et al. Three-years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naive patients with undetectable HBV DNA: results from studies ETV-023 and -050 [abstract no. 714]. J Hepatol 2008; 48 (2 Suppl.): 266-7
60. Mochida S, Takaguchi K, Yokosuka O, et al. Long term efficacy, safety and resistance analyses of entecavir treatment in Japanese nucleoside-naive patients with chronic hepatitis B [abstract no. 703]. J Hepatol 2008; 48 Suppl. 2: 262
61. Katano Y, Kumada H, Kobashi H, et al. Histologic assessment of long-term entecavir treatment in chronic hepatitis B patients [abstract no. 889]. Hepatology 2008; 48 (4 Suppl.): 703-4
62. Chang TT, Wu SS, Chao YC, et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901 [abstract plus poster no. PE119]. 19th Conference of the Asian Pacific Association for the Study of the Liver; 2009 Feb 13-16; Hong Kong
63. Lee J, Kim H, Park J, et al. Comparison between clevudine and entecavir treatment for antiviral naive patients with chronic hepatitis B [abstract no. P0920]. Gut 2008; 57 Suppl. 2: 288
64. Sherman M, YurdaydinC, Simsek H, etal. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008 Jul; 48 (1): 99-108
65. Pellicelli AM, Barbaro G, Barbarini G, et al. Efficacy of en-tecavir as rescue therapy in lamivudine-resistant patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation [abstract no. 885]. Hepatology 2008; 48 (4 Suppl.): 701-2
66. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86 (4): 611-4
67. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103 (11): 2776-83
68. Dienstag JL, Wei LJ, Xu D, et al. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007; 27 (1): 35-49
69. Pessoa MG, Gazzard B, Huang AK, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coin-fected patients receiving lamivudine as part of anti-retroviral therapy. AIDS 2008; 22 (14): 1779-87
70. Brosa M, Buti M, Staginnus U, et al. Modeling the long term consequences of suppressing viral replication in chronic hepatitis B: a cost-effectiveness analysis of entecavir in Spain [abstract no. PIN35]. Value Health 2007; 10 (6): A446. Plus poster presented at the International Society for Pharmacoeconomic Outcomes and Research 10th Annual European Congress; 2007 Oct 20-23; Dublin
71. Deniz B, Buti M, Brosa M, et al. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir), lamivu-dine, adefovir dipivoxil (adefovir) and entecavir of HBEAG negative patients with chronic hepatitis-B in Spain [abstract no. 558]. J Hepatology 2008; 48 Suppl. 2: 209. Plus poster presented at the 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
72. Deniz HB, Everhard F. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate, lamivudine, adefovir dipivoxil and entecavir in HBEAG negative (-) patients with chronic hepatitis B in the USA [abstract no. 976]. Hepatology 2008; 48 (4 Suppl.): 744-5. Plus poster presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31-Nov 4; San Francisco (CA)
73. Buti M, Brosa M, Casado MA, et al. Modeling the long-term cost-effectiveness of chronic hepatitis B therapies in Spain [poster no. PG112]. International Society for Phar-macoeconomic Outcomes and Research 11th Annual European Congress; 2008 Nov 8-11; Athens
74. Orlewska E, Cerri KH, Kutikova L, et al. The cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B patients in Poland [abstract no. PIN12]. Value Health 2007; 10 (6): A162-3. Plus poster presented at the 12th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2007 May 19-23; Arlington (VA)
75. Lee KK, Lee VWY, Yuan Y. Cost-effectiveness of substituting lamivudine with entecavir in chronic hepatitis B patients in the public sector of Hong Kong [abstract no. PIN11]. Value Health 2007; 10 (6): 162. Plus poster presented at the 12th International Meeting of the International Society for Pharmacoeconomic Outcomes and Research; 2007 May 19-23; Arlington (VA)
76. Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manage Care Pharm 2008; 14 (1): 21-33
77. Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25 (11): 963-77
78. Yuan Y, Iloeje U, Li H, et al. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008; 11 Suppl. 1: 11-22
79. Lok ASF, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007; 45 (2): 507-39
80. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-83
81. Dienstag JL. Drug therapy: hepatitis B virus infection. N Engl J Med 2008; 359 (14): 1486-500
82. Liaw Y-F, Chu C-M. Hepatitis B virus infection. Lancet 2009; 373: 582-92
83. Hirsch MS. Entecavir surprise. N Engl J Med 2007; 356 (25): 2641-3
84. Gaglio PJ, Sterling R, Daniels E, et al. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy. Clin Infect Dis 2007; 45 (5): 618-23